Biomedical Engineering Reference
In-Depth Information
75. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de
Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish
tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874
76. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner
M, Schoenherr A, Koeppen S et al (2005) A human protein-protein interaction network: a
resource for annotating the proteome. Cell 122:957-968
77. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV,
Lawrence M, Sougnez C, McKenna A et al (2011) The mutational landscape of head and
neck squamous cell carcinoma. Science 333(6046):1157-1160
78. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A,
Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A
102:15545-15550
79. Sun W, Pierce E, Vicini P (2011) Development of a physiologically-based pharmacokinetic
(PBPK) model of Vandetanib. AAPS J 13:R6353
80. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-
Viqueira B, Hidalgo M (2009) Characterizing DNA methylation patterns in pancreatic cancer
genome. Mol Oncol 3:425-438
81. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes
and core pathways. Nature 455:1061-1068
82. TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615
83. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S,
Cao X, Tchinda J, Kuefer R et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science 310:644-648
84. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor
microenvironment. J Natl Cancer Inst 99:1441-1454
85. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the
ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121
86. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy
K, Marton MJ, Witteveen AT et al (2002) Gene expression profiling predicts clinical outcome
of breast cancer. Nature 415:530-536
87. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse
HL, Roberts C, Marton MJ et al (2002) A gene-expression signature as a predictor of survival
in breast cancer. N Eng J Med 347:1999-2009
88. van der Graaf PH, Benson N (2011) Systems pharmacology: bridging systems biology and
pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm
Res 28:1460-1464
89. von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N, Yamada
K, Lamond A, Kalna G, Orton R et al (2009) Cell fate decisions are specified by the dynamic
ERK interactome. Nat Cell Biol 11:1458-1464
90. Weinstein IB (2002) Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science
297:63-64
91. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact
HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and
perturbed pRb cell cycle control. Oncogene 21:1510-1517
92. Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ (1992) Orthotopic and ectopic organ
environments differentially influence the sensitivity of murine colon carcinoma cells to
doxorubicin and 5-fluorouracil. Int J Cancer 52:98-104
93. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS,
Hop CE et al (2012) Anti-tumor activity of targeted and cytotoxic agents in murine subcuta-
neous tumor models correlates with clinical response. Clin Cancer Res Off J Am Assoc
Cancer Res 18(14):3846-3855
Search WWH ::
Custom Search